Leuthold Group LLC Purchases Shares of 23,517 Biogen Inc. $BIIB

Leuthold Group LLC purchased a new position in Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 23,517 shares of the biotechnology company’s stock, valued at approximately $3,294,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Elevation Point Wealth Partners LLC bought a new stake in shares of Biogen in the second quarter worth about $25,000. Rothschild Investment LLC raised its position in Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the last quarter. Concord Wealth Partners lifted its holdings in Biogen by 100.0% in the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after buying an additional 114 shares during the period. NewSquare Capital LLC increased its stake in shares of Biogen by 134.6% during the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares during the period. Finally, WFA of San Diego LLC bought a new position in shares of Biogen during the second quarter valued at approximately $32,000. 87.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

BIIB has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price objective on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Mizuho increased their price target on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday. Oppenheimer upped their target price on Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Tudor Pickering set a $201.00 target price on Biogen in a research note on Monday. Finally, TD Cowen lifted their price target on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday. Thirteen analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $206.54.

Biogen Stock Up 1.2%

NASDAQ:BIIB opened at $191.20 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The firm has a market cap of $28.06 billion, a P/E ratio of 21.70, a P/E/G ratio of 1.50 and a beta of 0.16. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The firm has a 50-day simple moving average of $177.65 and a two-hundred day simple moving average of $158.12.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the prior year, the company posted $3.44 earnings per share. The business’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Multiple brokers raised price targets and reiterated constructive views (Mizuho raised its target to $236; other shops including Citigroup, Oppenheimer, RBC and HC Wainwright also bumped targets or highlighted upside), which supports near‑term buying interest. Read More. Read More.
• Positive Sentiment: Pipeline progress and commercial outlook improved investor sentiment — recent coverage highlights advances outside Alzheimer’s (lupus, SMA) and management’s updated guidance/earnings beat that underpin the longer‑term growth story beyond legacy MS products. Read More.
• Neutral Sentiment: Board leadership change announced — long‑time chair Caroline Dorsa is retiring and the board elected Dr. Maria C. Freire as chair effective immediately; governance shifts are material but not an immediate operational catalyst. Read More.
• Neutral Sentiment: Reported short‑interest notes in feeds appear inconsistent (entries show zero shares and NaN changes), so there’s no clear short‑covering signal to explain price moves.
• Negative Sentiment: Insider selling disclosed — senior insider Priya Singhal sold 2,660 shares (SEC Form 4 filed), which can be interpreted by some investors as a modest negative signal even though the sale size is limited relative to total float. Read More.
• Negative Sentiment: Execution and franchise risks remain — analysts and commentators still flag pressure in the legacy MS business and the challenge of scaling Leqembi access/commercial execution, which could limit upside if execution falters. Read More.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.